The Philadelphia Inquirer recently covered Fideres’s recent research on price increases of generic drugs as part of a full examination of the pharmaceutical industry.
Alberto Thomas, founding partner at Fideres, is quoted as describing the price increases as occurring “without any meaningful increases in the costs of materials or production costs or breakdown of factories or other disruption to the supply chain. That’s what makes this very suspicious.”
The full article by the Philadelphia Inquirer can be found here.
